Seventh, while SGLT‐2 inhibitors have shown benefits in patients with both type 2 diabetes and CAD, not all patients with diabetes have indications for these agents—particularly those without significant renal or cardiovascular complications. Here, SLC5A2 is linked to diabetes mellitus.